Here are four insights:
1. Cambridge, Mass.-based InVivo Therapeutics’ INSPIRE Study tests the Neuro-Spinal Scaffold’s efficacy and safety for complete thoracic AIS A spinal cord injury.
2. Patrick Hsieh, MD, principal investigator at the site, implanted the device in the patient about 82 hours post SCI.
3. Dr. Hsieh has now implanted two patients with the Neuro-Spinal Scaffold.
4. With the addition of this patient, InVivo now has 12 patients enrolled and in follow-up.
More articles on devices:
Consensus launches wearable post-surgical device
SI-Bone launches SI Joint Women’s Health Initiative — 4 observations
Boston Scientific: device tax suspension added over 2K jobs — 5 takeaways
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
